Cargando…
PD‐L1 in gestational trophoblastic disease: an antibody evaluation
INTRODUCTION: Treatment with antibodies directed against programed‐cell death ligand 1 (PD‐L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD‐L1 expression in tumor tissue is commonly used to identify patients who might benefit from anti‐PD‐L1 treatment. Mul...
Autores principales: | Hoeijmakers, Yvonne M., Simons, Michiel, Bulten, Johan, Gorris, Mark A. J., Ottevanger, Petronella B., de Vries, I. Jolanda M., Sweep, Fred C. G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564454/ https://www.ncbi.nlm.nih.gov/pubmed/35689468 http://dx.doi.org/10.1111/aogs.14404 |
Ejemplares similares
-
Risk factors for second‐line dactinomycin failure after methotrexate treatment for low‐risk gestational trophoblastic neoplasia: a retrospective study
por: Hoeijmakers, YM, et al.
Publicado: (2020) -
Extravillous trophoblast invasion and decidualization in cesarean scar pregnancies
por: Gao, Lufen, et al.
Publicado: (2022) -
Fetal sex and the development of gestational diabetes mellitus in gravidae with multiple gestation pregnancies
por: Sassin, Alexa M., et al.
Publicado: (2023) -
External validation and clinical utility of prognostic prediction models for gestational diabetes mellitus: A prospective cohort study
por: Meertens, Linda J. E., et al.
Publicado: (2020) -
Risk of gestational diabetes mellitus in relation to early pregnancy and gestational weight gain before diagnosis: A population‐based cohort study
por: Xu, Huiling, et al.
Publicado: (2022)